A R T I C L E S
Bai et al.
Figure 6. γ-H2AX immunofluorescence in B16F1 cells after incubation (A) with and (B) without treatment with 5 µM 9f for 48 h. The arrows indicate
γ-H2AX foci (red) and the Hoechst-33258 dye (blue) localizes the nuclear DNA.
chem), and propidium iodide (Sigma-Aldrich). UV spectra were
measured on a Shimadzu 2550 UV-vis double-beam spectropho-
tometer. Fluorescence spectra were collected on PerkinElmer LS
55 fluorimeter. The excitation and emission slit widths were both
set to 10 nm. All of the cell imaging was performed with a Nikon
confocal laser scanning microscope (TE2000, Japan). Images and
merges were obtained with EZ-C1 software.
All other chemicals were purchased from Sigma-Aldrich and used
as received. All new compounds were fully characterized by HRMS
and 1H NMR and 13C NMR spectroscopy. 1H and 13C NMR spectra
were recorded on Varian Mercury 300 and 600 spectrometers,
respectively. Chemical shifts were reported as δ values relative to
the internal standard tetramethylsilane. HRMS spectra were recorded
on a Bruker APEX IV (7.0 T) ESI-QTPF mass spectrometer (Bruker
Daltonik GmbH, Bremen, Germany) and an APEX II FT-ICR
instrument.
General Procedure for the Synthesis of 2,3-Dihydroxy Deriva-
tives 6a-f and 3,4-Dihydroxy Derivatives 9a-f. The symmetrical
bis(catechol) quaternary ammonium derivatives 5a-f and 8a-f
were prepared through condensation of the corresponding dibromo
compounds with (2,3-dimethoxybenzyl)dimethylamine (4) and (3,4-
dimethoxybenzyl)dimethylamine (7), respectively. Demethylation
reactions of compounds 5a-f and 8a-f were performed in 1:1
HOAc/40% HBr cosolvents, affording the compounds 6a-f and
9a-f in good yields. Compounds 4 and 7 were synthesized
according to our previously published procedure.6 4,4′-Bis(bro-
momethyl)biphenyl was synthesized according to a previously
published procedure.20
Alkaline Agarose Gel Electrophoresis Assay. The duplex DNA
was linearized by restriction endonuclease digestion with EcoR I.
DNA cross-linking experiments were carried out in 10 mM
phosphate buffer (pH 6.4). Samples were incubated with 40 units
of mushroom tyrosinase in the presence of atmospheric O2 at 37
°C for 30 min. The crude reaction mixtures were loaded onto a
denaturing 0.9% alkaline agarose gel. The gel was stained in
ethidium bromide (0.5 µg/mL) for 30 min and subsequently washed
in water for 10 min. Gels were visualized by UV and photographed
using a Vilber Lourmat video system.
cross-link DNA through the formation of bis(o-quinone) by
tyrosinase-dependent oxidation. We have shown that DNA
cross-linking may lead to specific and potent targeting of
tyrosinase-expressing cells. This novel therapeutic strategy
induces cytotoxicity to melanoma cells. This may well provide
a possible chemotherapy for melanoma that employs tyrosinase-
activated agents that can induce cytotoxic DNA double-stand
breaks.
Experimental Section
Materials and Apparatus. The following compounds and
reagents were commercially available: tyrosinase mushroom (Sigma),
MBTH (Sigma), reduced glutathione (Sigma), MEM (HyClone,
Thermo Scientific), RPMI 1640 medium (GIBCO), fetal bovine
serum (FBS, HyClone), penicillin and streptomycin (Invitrogen),
MTT (Sigma), γ-H2AX (phosphor S139) rabbit polyclonal (ab11174,
Abcam), Hoechst-33258 (Calbiochem), Hoechst-33324 (Calbio-
(13) (a) Domaille, D. W.; Zeng, L.; Chang, C. J. J. Am. Chem. Soc. 2010,
132, 1194–1195. (b) Devaraj, N. K.; Hilderbrand, S.; Upadhyay, R.;
Mazitschek, R.; Weissleder, R. Angew. Chem., Int. Ed. 2010, 49, 2869–
2872.
(14) (a) Pallardo´, F. V.; Markovic, J.; Garc´ıa, J. L.; Vin˜a, J. Mol. Aspects
Med. 2009, 30, 77–85. (b) Gad, S. C. Glutathione 1998, 2, 53–54.
(15) (a) Potters, G.; Jansen, M. A. K.; Horemans, N.; Guisez, Y.; Pasternak,
T. In Vitro Cell. DeV. Biol.: Plant 2010, 46, 289–297. (b) Kudugunti,
S. K.; Vad, N. M.; Whiteside, A. J.; Naik, B. U.; Yusuf, M. A.;
Srivenugopal, K. S.; Moridani, M. Y. Chem. Biol. Interact. 2010, 188,
1–14. (c) Manini, P.; Napolitano, A.; Westerhof, W.; Riley, P. A.;
d’Ischia, M. Chem. Res. Toxicol. 2009, 22, 1398–1405.
(16) (a) Muniandy, P. A.; Liu, J.; Majumdar, A.; Liu, S.; Seidman, M. M.
Crit. ReV. Biochem. Mol. Biol. 2010, 45, 23–49. (b) Sczepanski, J. T.;
Jacobs, A. C.; Houten, B. V.; Greenberg, M. M. Biochemistry 2009,
48, 7565–7567. (c) Wood, R. D. EnViron. Mol. Mutagen. 2010, 51,
510–526. (d) Hinz, J. M. EnViron. Mol. Mutagen. 2010, 51, 582–
603.
(17) (a) Doria, F.; Richter, S. N.; Nadai, M.; Colloredo-Mels, S.; Mella,
M.; Palumbo, M.; Freccero, M. J. Med. Chem. 2007, 50, 6570–6579.
(b) Cederberg, H.; Henriksson, J.; Binderup, M. L. Mutagenesis 2010,
¨
25, 133–138. (c) Eren, K.; Ozmeric¸, N.; Sardas¸, S. Clin. Oral InVest.
2002, 6, 150–154.
BMTH Assay. Compound 9f (500 µM) was incubated with 40
units of mushroom tyrosinase in the presence of atmospheric O2
and 1 mM MBTH for 1 h. MBTH solutions were freshly prepared
before use. The spectrum was measured on UV-vis spectropho-
tometer.
(18) (a) Kinner, A.; Wu, W. Q.; Staudt, C.; Iliakis, G. Nucleic Acids Res.
2008, 36, 5678–5694. (b) Cowell, I. G.; Sunter, N. J.; Singh, P. B.;
Austin, C. A.; Durkacz, B. W.; Tilby, M. J. PLoS One 2007, 10, e1057.
(19) (a) Gomez, D.; Wenner, T.; Brassart, B.; Douarre, C.; O’Donohue,
M. F.; Khoury, V. E.; Shin-ya, K.; Morjani, H.; Trentesaux, C.; Riou,
J. F. J. Biol. Chem. 2006, 281, 38721–38729. (b) Yao, K.; Wu, W.;
Yu, Y. B.; Zeng, Q. L.; He, J. L.; Lu, D. Q.; Wang, K. J. InVest.
Ophthalmol. Visual Sci. 2009, 49, 2009–2015.
(20) Helms, A.; Heiler, D.; McLendon, G. J. Am. Chem. Soc. 1992, 114,
6227–6238.
9
15326 J. AM. CHEM. SOC. VOL. 132, NO. 43, 2010